GOODPASTURE'S SYNDROME: PATHOGENESIS, DIAGNOSIS, TREATMENT


Cite item

Full Text

Abstract

Goodpasture's syndrome (GS) is a combination of severe acute hemorrhagic alveolitis with severe respiratory failure and malignant glomerulonephritis. Data on the etiology, pathogenesis, clinical presentation, diagnosis and treatment of GS are presented. It is emphasized that GS remains disease with largely unfavorable outcome in most cases. However, the expansion of representations of its pathogenesis allows to discuss the development and introduction of new targeted therapies; in future, evidences of their effectiveness in GS should allow their application in other variants of pulmonary-renal syndrome, especially when the patient has malignant glomerulonephritis.

References

  1. Мухин Н.А. Синдром Гудпасчера. В кн. Нефрология (руководство для врачей). М., 2000.
  2. Bosch X, Font J. The pulmonary-renal syndrome: a poorly understood clinicopathologic condition. Lupus 1999;8:258-62.
  3. Алмазов В.А., Журавлев В.А., Наймарк Д.А., Петров М.Н. Капиллярит с преимущественным поражением сосудов почек и легких (синдром Goodpasture) // Клин. мед. 1972. № 10. С. 140-45.
  4. Uezu Y, Kiyatake I, Tokuyama K. A case of Goodpasture's syndrome with massive pulmonary hemorrhage ameliorated by cyclophosphamide pulse therapy. Nippon Jinzo Gakkai Shi 1999;41:499-504.
  5. Daly C, Conlon PJ, Medwar W, Walshe JJ. Characteristics and outcome of anti-glomerular basement membrane disease: a single-center experience. Ren Fail 1996;18:105-12.
  6. Shah MK, Hugghins SY. Characteristics and outcomes of patients with Goodpasture's syndrome. South Med J 2002;95:1411-8.
  7. Hirayama K, Yamagata K, Kobayashi M, Koyama A. Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol 2008;12(5):339-47.
  8. von Vigier RO, Trummler SA, Laux-End R, et al. Pulmonary renal syndrome in childhood: a report of twenty-one cases and a review of the literature. Pediatr Pulmonol 2000;29:382-8.
  9. Bergs L. Goodpasture syndrome. Crit Care Nurs 2005;25:50-8.
  10. Hammerschmidt DE. Ernest Goodpasture and glomerulonephritis. J Lab Clin Med 2002;139:324.
  11. Murphy TE. A case report of Goodpasture syndrome is described and discussed in terms of insurability. J Insur Med 2000;32:189-90.
  12. Jung C, Karpouzas G, Stringer WW. Dyspnea, hemoptysis, and perihilar infiltrates in a 35-year-old man. Chest 2005;127:1437-41.
  13. Calderon EJ, Wichmann I, Varela JM, et al. Presence of glomerular basement membrane (GBM) antibodies in HIV-patients with Pneumocystis carinii pneumonia. Clin Exp Immunol 1997;107:448-50.
  14. Tsagalis GC, Margelos V, Nikolopoulou N, Hadjiconstantinou VE. Fluctuating levels of anti-GBM antibodies following a fungal infection in a patient with secondary amyloidosis. Clin Nephrol 2003;59:150-52.
  15. Lucas Guillen E, Martinez Ruiz A, Alegria Fernandez M, Martinez Losa A. Goodpasture syndrome: re-exacerbations associated with intercurrent infections. Rev Clin Esp 1995;195:761-64.
  16. Turner-Warwick M. Adverse reactions affecting the lung: possible association with D-penicillamine. J Rheumatol 1981;7:166-68.
  17. Stetter M, Schmidl M, Krapf R. Azathioprine hypersensitivity mimicking Goodpasture's syndrome. Am J Kidney Dis 1994;23:874-7.
  18. Shah MK. Outcomes in patients with Goodpasture's syndrome and hydrocarbon exposure. Ren Fail 2002;24:545-55.
  19. Sirvent AE, Enriquez R, Andrada E, et al. Goodpasture's syndrome in a patient using cocaine - a case report and review of the literature. Clin Nephrol 2007;68(3):182-85.
  20. Kalluri R, Petrides S, Wilson CB, et al. Anti-alpha 1 (IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome. Ann Intern Med 1996;124:651-53.
  21. Au WY, Tang SC, Chan KW, et al. Pulmonary renal syndrome and thrombotic thrombocytopenic purpura in a patient with giant cavernous hemangioma of the leg. Arch Intern Med 2002;162:221-22.
  22. Persson U, Hertz JM, Carlsson M, et al. Patients with Goodpasture's disease have two normal COL4A3 alleles encoding the NC1 domain of the type IV collagen alpha 3 chain. Nephrol Dial. Transplant 2004;19:2030-35.
  23. Ball JA, Young KR. Pulmonary manifestations of Goodpasture's syndrome. Antiglomerular basement membrane disease and related disorders. Clin Chest Med 1998;19:777-91.
  24. Rutgers A, Meyers KE, Canziani G, et al. High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha 3 (IV) NC1 collagen. Kidney Int 2000;58:115-22.
  25. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003;348:2543-56.
  26. Hellmark T, Segelmark M, Unger C, et al. Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int 1999;55:936-44.
  27. Gunnarsson A, Hellmark T, Wieslander J. Molecular properties of the Goodpasture epitope. J Biol Chem 2000;275:30844-48.
  28. Wu J, Borillo J, Glass WF, et al. T-cell epitope of alpha3 chain of type IV collagen induces severe glomerulonephritis. Kidney Int 2003;64(4):1292-301.
  29. Zou J, Henderson L, Thomas V, et al. Presentation of the Goodpasture autoantigen requires proteolytic unlocking steps that destroy prominent T cell epitopes. J Am Soc Nephrol 2007;18(3):771-79.
  30. Zhao J, et al. Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease. Nephrol Dial Transplant 2009;24(6):1838-44.
  31. Zhao J, Yan Y, Cui Z, et al. The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rH alpha 3 (IV) NC1 is associated with disease severity. Hum Immunol 2009;70(6):425-29.
  32. Chikamitsu H. Experimentelle studien uber immunocytotoxische glomerulonephritis. Folia Endocrin Japan 1940;40:85.
  33. Reynolds J, Moss J, Duda MA, et al. The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease. J Pathol 2003;200:118-29.
  34. Borza DB. Autoepitopes and alloepitopes of type IV collagen: role in the molecular pathogenesis of anti-GBM antibody glomerulonephritis. Nephron Exp Nephrol 2007;106:37-43.
  35. Salama AD, Chaudhry AN, Ryan JJ, et al. In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3 (IV) NC1. J Am Soc Nephrol 2001;12:1908-15.
  36. Dean EG, Wilson GR, Li M, et al. Experimental autoimmune Goodpasture's disease: a pathogenetic role for both effector cells and antibody in injury. Kidney Int 2005;67:566-75.
  37. Okada H, Moriwaki K, Kalluri R, et al. Inhibition of monocyte chemoattractant protein-1 expression in tubular epithelium attenuates tubulointerstitial alteration in rat Goodpasture syndrome. Kidney Int 2000;57:927-36.
  38. Kuroda T, Yoshida Y, Kamiie J, et al. Expression of MMP-9 in mesangial cells and its changes in anti-GBM glomerulonephritis in WKY rats. Clin Exp Nephrol 2004;8(3):206-15.
  39. Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. Clin Chest Med 2004;25:583-92.
  40. Jung C, Karpouzas G, Stringer WW. Dyspnea, hemoptysis, and perihilar infiltrates in a 35-year-old man. Chest 2005;127:1437-41.
  41. Ball JA, Young KR. Pulmonary manifestations of Goodpasture's syndrome. Antiglomerular basement membrane disease and related disorders. Clin Chest Med 1998;19:777-91.
  42. Salama AD, Levy JB, Lightstone L, Pusey CD. Goodpasture's disease. Lancet 2001;358:917-20.
  43. Sethi S, Lewin M, Lopez L, Lager D. Linear anti-glomerular basement membrane IgG but no glomerular disease: Goodpasture's syndrome restricted to the lung. Nephrol Dial Transplant 2007;22(4):1233-35.
  44. Sengul E, Eyileten T, Ozcan A, et al. Anti-glomerular basement membrane disease with nephrotic proteinuria. Clin Nephrol 2009;72(2):157-59.
  45. Gallagher H, Kwan JT, Jayne DR. Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis 2002;39:42-7.
  46. Kalluri R. Goodpasture syndrome. Kidney Int 1999;55:1120-22.
  47. Zhao M, Ding J, Liu Y, et al. A clinical and pathological analysis of 41 patients with anti-glomerular basement membrane antibody related diseases. Zhonghua Nei Ke Za Zhi 2001;40:316-20.
  48. Vuckovic B, Ilic T, Mitic I, et al. Goodpasture's syndrome - case report. Med Pregl 2004;57:391-95.
  49. Sharma S. Bilateral serous retinal detachments associated with Goodpasture's syndrome. Can J Ophthalmol 1998;33:226-7.
  50. Chak M, Stanford MR, Poon W, et al. Uveitis initiating an autoimmune reaction resulting in Goodpasture's syndrome in a Chinese man. Br J Ophthalmol 2002;86:1188-90.
  51. Blanco Filho F, Ernesto LC, Rosa MA, et al. Rapidly progressive antineutrophil cytoplasm antibodies associated with pulmonary-renal syndrome in a 10-year-old girl. Sao Paulo Med J 2001;119:29-32.
  52. Verburgh CA, Bruijn JA, Daha MR, van Es LA. Sequential development of anti-GBM nephritis and ANCA-associated Pauci-immune glomerulonephritis. Am J Kidney Dis 1999;34:344-48.
  53. Kalluri R, Meyers K, Mogyorosi A, et al. Goodpasture syndrome involving overlap with Wegener's granulomatosis and anti-glomerular basement membrane disease. J Am Soc Nephrol 1997;8:1795-800.
  54. Serratrice J, Chiche L, Dussol B, et al. Sequential development of perinuclear ANCA-associated vasculitis and anti-glomerular basement membrane glomerulonephritis. Am. J. Kidney Dis 2004;43:e26-e30.
  55. Henderson RD, Saltissi D, Pender MP. Goodpasture's syndrome associated with multiple sclerosis. Acta Neurol Scand 1998;98:134-35.
  56. Carreras L, Poveda R, Bas J, et al. Goodpasture syndrome during the course of a Schonlein-Henoch purpura. Am J Kidney Dis 2002;39:E21.
  57. Drube S, Maurin N, Sieberth HG. Coincidence of myasthenia gravis and antiglomerular basement membrane glomerulonephritis: a combination of two antibody-mediated autoimmune diseases on day 15. Nephrol Dial Transplant 1997;12:1478-80.
  58. Nakamura T, Suzuki Y, Koide H. Granulocyte and monocyte adsorption apheresis in a patient with antiglomerular basement membrane glomerulonephritis and active ulcerative colitis. Am J Med Sci 2003;325:296-98.
  59. Komatsu T, Utsunomiya K, Oyaizu T. Goodpasture's syndrome associated with primary biliary cirrhosis. Intern Med 1998;37:611-3.
  60. Kielstein JT, Helmchen U, Netzer KO, et al. Conversion of Goodpasture's syndrome into membranous glomerulonephritis. Nephrol Dial Transplant 2001;16:2082-85.
  61. Thitiarchakul S, Lal SM, Luger A, Ross G. Goodpasture's syndrome superimposed on membranous nephropathy. A case report. Int J Artif Organs 1995;18:763-5.
  62. Hecht N, Omoloja A, Witte D, et al. Evolution of antiglomerular basement membrane glomerulonephritis into membranous glomerulonephritis. Pediatr Nephrol 2008;23(3):477-80.
  63. Gartenschlager M, Lenci G, Schinzel H, et al. Goodpasture syndrome: treatment initiation with plasmapheresis before histologic diagnostic verification. Pneumologie 1996;50:764-68.
  64. Laczika K, Knapp S, Derfler K, et al. Immunoadsorption in Goodpasture's syndrome. Am J Kidney Dis 2000;36:392-25.
  65. Baumgartner I, Gmur J, Fontana A, et al. Recovery from life threatening pulmonary hemorrhage in Goodpasture's syndrome after plasmapheresis and subsequent pulse dose cyclosphosphamide. Clin Nephrol 1995;43:68-70.
  66. Garcia-Canton C, Toledo A, Palomar R, et al. Goodpasture's syndrome treated with mycofenolat mofetil. Nephrol Dial Transplant 2000;15:920-22.
  67. Takeda S, Takahashi M, Sado Y, et al. Prevention of glomerular crescent formation in glomerulonephritis by mycophenolate mofetil in rats. Nephrol Dial Transplant 2004;19(9):2228-36.
  68. Asgeirsdottir SA, Zwiers PJ, Morselt HW, et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am J Physiol Renal Physiol 2008;294(3):554-61.
  69. Garcia GE, Truong LD, Li P, et al. Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am J Pathol 2007;170(5):1485-96.
  70. Huang L, Garcia G, Lou Y, et al. Anti-inflammatory and renal protective actions of stanniocalcin-1 in a model of anti-glomerular basement membrane glomerulonephritis. Am J Pathol 2009;174(4):1368-78.
  71. Leh S, Vaagnes O, Margolin SB, et al. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrol Dial Transplant 2005;20(1):71-82.
  72. Netzer KO, Merkel F, Weber M. Goodpasture syndrome and end-stage renal failure - to transplant or not to transplant? Nephrol Dial Transplant 1998;13:1346-48.
  73. Miyazato M, Koyama Y, Miyazato T, et al. Cadaveric renal transplantation for Goodpasture's syndrome: a case report. Hinyokika Kiyo 2001;47:493-95.
  74. Hibbs AM, Bznik-Cizman B, Guttenberg M, et al. Ulcerative colitis in a renal transplant patient with previous Goodpasture disease. Pediatr Nephrol 2001;16:543-46.
  75. Khandelwal M, McCormick BB, Lajoie G, et al. Recurrence of anti-GBM disease 8 years after renal transplantation. Nephrol Dial Transplant 2004;19(2):491-94.
  76. Sauter M, Schmid H, Anders HJ, et al. Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy. Clin Transplant 2009;23(1):132-36.
  77. Saurina A, Arrizabalaga P, Rodriguez R, et al. Anti-glomerular basement membrane antibody mediated disease: revision of 32 cases and follow-up at one year of the diagnosis. Nefrologia 2003;23:415-22.
  78. Segelmark M, Hellmark T, Wieslander J. The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract 2003;94:59-68.
  79. Schindler R, Kahl A, Lobeck H, et al. Complete recovery of renal function in a dialysis-dependent patient with Goodpasture syndrome. Nephrol Dial Transplant 1998;13:462-6.
  80. Schmidt RH, Sieh S, Rohl D, et al. Spontaneous remission of Goodpasture syndrome in a 21-year-old patient. Dtsch Med Wochenschr 1999;124:1201-03.
  81. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001;134:1033-42.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies